David Emerson Jorden

Chief Financial Officer

Nuo Therapeutics, Inc.

Insider activity · 24 months2 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 1 saleDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 2 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

171

Companies

▲ Purchases (122 ops.)

€1.8M

▼ Sales (13 ops.)

€630k

Latest filing published 31 Aug 2026 for Nuo Therapeutics, Inc., €724.

Filing timeline

BuySale

David Emerson Jorden

Insider track record

Disclosed buys

122

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

David Emerson Jorden: trading record in brief

David Emerson Jorden is a declared insider at 4 companies (chief executive); the most frequent names are Nuo Therapeutics, Inc., Acer Therapeutics Inc. and PLx Pharma Inc. Between 30 September 2008 and 28 August 2026, the trades on record add up to 171 filings.

In open-market terms, that means 122 purchases worth €1.8M on one side and 13 sales worth €630k on the other. On balance, insiders were net buyers of €1.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 12 share grants and 3 option exercises. Since January 2026: 2 purchases and no sales on the market.

The median purchase comes to €7,767.

The newest entry dates from 31 August 2026: an open-market purchase of €7,457, in Nuo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.